InMed Pharmaceuticals Files S-1/A Amendment
Ticker: INM · Form: S-1/A · Filed: Dec 30, 2024 · CIK: 1728328
| Field | Detail |
|---|---|
| Company | Inmed Pharmaceuticals INC. (INM) |
| Form Type | S-1/A |
| Filed Date | Dec 30, 2024 |
| Risk Level | medium |
| Pages | 8 |
| Reading Time | 9 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, s-1/a, offering
TL;DR
InMed Pharma filed an S-1/A, looks like they're raising cash soon.
AI Summary
InMed Pharmaceuticals Inc. filed an S-1/A amendment on December 30, 2024, for its registration statement. The filing relates to a proposed offering of securities, though specific dollar amounts and dates for the offering are not detailed in this excerpt. The company is incorporated in British Columbia and headquartered in Vancouver.
Why It Matters
This filing indicates InMed Pharmaceuticals is moving forward with a securities offering, which could provide capital for its operations and drug development pipeline.
Risk Assessment
Risk Level: medium — As a pharmaceutical company pursuing an offering, InMed faces typical biotech risks related to drug development, regulatory approval, and market reception of its securities.
Key Numbers
- 2834 — SIC Code (Pharmaceutical Preparations industry)
Key Players & Entities
- InMed Pharmaceuticals Inc. (company) — Registrant
- December 30, 2024 (date) — Filing Date
- 333-284029 (registration_number) — SEC Registration Number
- Vancouver, British Columbia, Canada (location) — Company Headquarters
- Netta Jagpal (person) — Chief Financial Officer
FAQ
What is the purpose of this S-1/A filing?
This is a pre-effective amendment to a Form S-1 registration statement, indicating InMed Pharmaceuticals Inc. is updating its filing for a proposed public offering of securities.
When was this amendment filed?
The amendment was filed with the SEC on December 30, 2024.
Where is InMed Pharmaceuticals Inc. based?
The company's principal executive offices are located at Suite 1445 – 885 West Georgia St., Vancouver, British Columbia, Canada.
What is the company's Standard Industrial Classification (SIC) code?
InMed Pharmaceuticals Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Who is listed as an agent for service for this filing?
Registered Agent Solutions, Inc. at 1100 H Street NW, Suite 840, Washington, D.C. 20005 is listed as the agent for service.
Filing Stats: 2,349 words · 9 min read · ~8 pages · Grade level 9.2 · Accepted 2024-12-30 12:16:43
Filing Documents
- ea0226237-s1a1_inmedpharma.htm (S-1/A) — 56KB
- ea022623701ex5-1_inmed.htm (EX-5.1) — 12KB
- ex5-1_001.jpg (GRAPHIC) — 11KB
- 0001213900-24-113340.txt ( ) — 85KB
Exhibits and Financial Statement Schedules
Item 16. Exhibits and Financial Statement Schedules (a) Exhibits Exhibit Number Description of Exhibit 2.1 Amended and Restated Agreement and Plan of Reorganization, dated as of October 13, 2021, by and among InMed Pharmaceuticals Inc., InMed LLC, BayMedica, Inc., BM REP, LLC, as the stockholder representative, and certain stockholders thereto (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the SEC on October 13, 2021). 3.1 Amended and Restated Articles of InMed Pharmaceuticals Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Registration 4.1 Form of Specific Common Share Certificate (incorporated by reference to Exhibit 4.3 to the Company’s Registration Statement on Form S-1 filed with the SEC on July 13, 2021). 4.2 Form of Common Shares Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on November 12, 2020). 4.3 Form of Common Shares Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on February 5, 2021). 4.4 Form of Series A Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 30, 2021). 4.5 Form of Pre-Funded Warrants (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the SEC on June 30, 2021). 4.6 Form of Preferred Investment Option (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 6, 2022). 4.7 Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the SEC on June 6, 2022). 4.8 Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.3 to the Company
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Vancouver, British Columbia, Canada, on December 30, 2024. INMED PHARMACEUTICALS INC. By: /s/ Eric A. Adams Name: Eric A. Adams Title: President and Chief Executive Officer Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities indicated and on December 30, 2024. Signature Title * President, Chief Executive Officer and Director Eric A. Adams (Principal Executive Officer) * Chief Financial Officer Netta Jagpal (Principal Financial Officer and Principal Accounting Officer) * Director Janet Grove * Director Andrew Hull * Director Bryan Baldasare * Director Nicole Lemerond *By: /s/ Eric A. Adams Eric A. Adams Attorney-in-fact 3 AUTHORIZED REPRESENTATIVE Pursuant to the requirements of Section 6(a) of the Securities Act of 1933, the undersigned has signed this registration statement, solely in its capacity as the duly authorized representative of InMed Pharmaceuticals Inc. in the United States, on December 30, 2024. Andrew Hull /s/ Andrew Hull Authorized Representative 4